Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY's AWARE-1 study demonstrated positive signal in TNBC

<< Previous

Bullboard Posts

Next >>

Comment by unNoteableon Jul 13, 2021 5:48pm

216 Views

Post# 33540025

RE:ONCY's AWARE-1 study demonstrated positive signal in TNBC

It's well and good showing efficacy in mice, but I thought the general aim of the company was to treat mBC in humans.

Murine trials once translated into humans will require 5-10 years before commercialisation. Without an approved product / partnership or outright buyout, ONCY won't last that long.

I know this doesn't fit your rose-tinted view of Oncolytics Biotech, but considering Pelareorep doesn't even work by a tumor lysis moa, perhaps ONCY could rebrand themselves as 'Purple Dye Pharma'. With pelareorep marketed as, 'just as safe a coloured water'.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec